Team

Darren Wakefield

 

Director of Chemistry

  • +16 Years of experience in the Chemical modification, bioconjugation and delivery of nucleic acids
  • Roche
  • MirusBio
  • Co-inventor in 50 US patents

 

Daniel Restrepo

 

Director of Business Development

  •  Strategic guidance in capital raising activities
  • Leverage cutting-edge financial tools and a network of global experts to ensure NanoSUR is at the forefront of sustainable growth
  • Cultivate strategic partnerships and investor networks

Graciela Arhancet

President

  • Director Innovation – Novus International (2010 -2017)
  • Leadership in Drug Discovery and Early
  • Development – Pfizer (1999-2020)
  • She is the autor and holder of more than fifty publications and patents

Juan Arhancet

 

CEO

  • CEO and founder of Apse Inc.
    (2010 -2016)
  • Associate Fellow – Monsanto
    (1999-2010)
  • Research Engineer – Shell
    (1991 -1999)
  • 45 granted US patents, and 9 publicantions

Andrew Fehretdinov

 

CFO

  • 15 Years of Financial management and accounting experience
  • CFO – Incentive Technology Group (2016-2020)
  • VP of Finance – Digital Management (2009 – 2014)

Vladimir Trubetskoy​

 

Director of Formulation

  • Principal Scientist – Arrowhead Pharmaceuticals
    (2011-2016)
  • Principal Scientist – Roche
    (2008-2011)
  • Senior Scientist – Mirus Bio
    (2006-2008)
  • He is co-author of 38 original researchs papers, 9 reviews/book chapter and co-inventor on 33 US patents

Our History

2017

NanoSUR's Foundation.

2018

- Start of phase I NSF-funded Project on new RNAi triggers.
- First patent on RNAi triggers granted.

2019

- Start of phase II NSF-funded Project on DBM control.
  - Start of phase I USDA-funded Project on RIFA control.

2020

- Scalable methods of manufacture developed.
- Additional composition of matter manuf.
- Patents filed.

2021

Start of phase I II USDA-funded projects
(gypsy moth RIFA).

2022

- Successful FIELD TRIALS in FL CA protecting two vegetables from a major pest (DBM).
- Additional Patents filed on manuf. of MdsRNA.

2023

Start of phase II USDA-funded project
(gypsy moth).

Logo Evolution
Inspiration
Growth
Success
Scroll to Top